Neurogene (NGNE) Stock Price, News & Analysis

Company Overview

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare and devastating neurological diseases. The company’s work centers on gene therapies designed to address severe neurodevelopmental and neurodegenerative disorders for which treatment options are limited.

Neurogene’s pipeline includes NGN-401, an investigational gene therapy being developed for Rett syndrome, and NGN-101, an investigational therapy targeting CLN5 disease, a form of neuronal ceroid lipofuscinosis also known as Batten disease. These programs are intended to deliver therapeutic genes to the central nervous system and are being evaluated in clinical development; the company does not currently have an approved commercial product.

The company also develops its proprietary EXACT gene-regulation platform, which is designed to help control gene expression and improve the safety and effectiveness of gene therapies. Neurogene was established to advance genetic medicines for serious neurological conditions and conducts its development activities through clinical studies involving patients in relevant treatment markets.

Key Stats

• Today's Range: $24.86 to $26.95
• 50-Day Range: $25.65 to $40.84
• 52-Week Range: $15.93 to $43.66
• Volume: 401,639 shs
• Average Volume: 310,825 shs
• Market Capitalization: $513.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $83.67
• Consensus Rating: Buy

Neurogene Stock Analysis - MarketRank™

Neurogene scored higher than 56% of companies evaluated by MarketBeat, and ranked 464th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Neurogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Neurogene has a consensus price target of $83.67, representing about 226.2% upside from its current price of $25.65.

Amount of Analyst Coverage

Neurogene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neurogene are expected to grow in the coming year, from ($5.80) to ($5.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neurogene is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neurogene is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neurogene has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.56% of the float of Neurogene has been sold short.

Short Interest Ratio / Days to Cover

Neurogene has a short interest ratio ("days to cover") of 16.85, which indicates bearish sentiment.

Change versus previous month

Short interest in Neurogene has recently increased by 4.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurogene does not currently pay a dividend.

Dividend Growth

Neurogene does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Neurogene has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Neurogene this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,358.00 in company stock.

Percentage Held by Insiders

11.68% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NGNE
• Previous Symbol: NASDAQ:NGNE
• CIK: 1404644
• Web: www.neurogene.com
• Phone: (877) 237-5020
• Fax: 778-331-4486
• Employees: 131
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Neurogene: $83.67
• High Price Target: $166.00
• Low Price Target: $50.00
• Potential Upside/Downside: +226.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$90.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -45.10%
• Return on Assets: -41.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.65
• Quick Ratio: 10.64

Sales & Book Value

• Annual Sales: $930 thousand
• Price / Sales: 551.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.10 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 20,010,000
• Free Float: 17,674,000
• Market Cap: $513.26 million
• Optionable: Optionable
• Beta: 1.70